ArticleBreast cancer (Dove Medical Press)2026
Receptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visceral metastases in breast cancer demonstrate considerable molecular heterogeneity. This study examines changes in receptor status and molecular subtypes between primary breast cancer and visceral metastases. Methods: A retrospective analysis was conducted on 430 patients diagnosed with breast cancer and visceral metastases, including 138 with lung metastases and 292 with liver metastases. Receptor statuses (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) were assessed in both primary and metastatic tumors. Discordance in molecular subtypes was assessed, and factors influencing receptor changes were identified. Survival outcomes were estimated using Kaplan-Meier analysis. Results: Receptor discordance was observed in 47.9% (206/430) of patients, with a higher frequency in liver metastases (51.0%) than in lung metastases (41.3%). PR discordance was the most frequent (36.2%), followed by ER (18.9%) and HER2 (7.2%). Molecular subtype discordance occurred in 36.1% of patients, with the highest rate in Luminal A tumors (85.7%). Multivariate analysis identified pN3 stage and molecular subtype as independent predictors. Kaplan-Meier survival analysis showed that patients with ER gain had significantly improved disease-free survival (DFS) compared with those with ER loss (75.4 vs 44.5 months, P = 0.0092). Moreover, molecular subtype discordance was associated with longer DFS (63.9 vs 49.1 months, P = 0.0079). Conclusion: This study emphasizes that there are significant differences in receptor expression and molecular subtypes between primary breast tumors and their visceral metastases. The receptor is more likely to change in patients with liver metastasis and Luminal A or Luminal B (HER2+) tumors, highlighting the importance of repeat biopsy in the metastatic environment. These findings can be used to identify high-risk patients and provide them with better treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.